Application Notes: Multiplexing: Standard

SARS-CoV-2 Reference Material Quantification on the Absolute Q dPCR Platform

Download Application note
 

To address the need for a reliable method of accurate and precise measurements of SARS-CoV-2 samples, we leverage the Combinati Absolute Q Digital PCR (dPCR) platform, to quantify commercially available SARS-CoV-2 reference control material.

IDT rhAmp EGFR p.T790M Genotyping on the Combinati Absolute Q

Download Application note Integrated DNA Technologies’ rhAmp SNP Genotyping System enables highly precise interrogation of SNPs within difficult genomic regions. For the first time, the IDT rhAmp assay performance was demonstrated on a digital PCR platform — quantifying EGFR p.T790M mutation down to 0.1%.

BCR/ABL Gene Expression Assay on the Combinati Absolute Q

Download Application note 95% of Chronic Myeloid Leukemia (CML) cases are characterized by the presence of a BCR-ABL1 fusion gene. Regular monitoring involving precise quantification of BCR-ABL1 transcripts is integral to successful tyrosine kinase inhibitor (TKI) treatment. Read more about how samples with precise ratios of BCR-ABL1/ABL1 were created and confirmed on the Combinati dPCR platform.

TaqMan™ Liquid Biopsy assays for rare target quantification

Download Application note Digital PCR (dPCR) enables rare target detection even in the presence of high non-target background. Read more about how the Applied Biosystems™ TaqMan™ Liquid Biopsy dPCR Assays were used to perform rare target detection for 5 hot-spot cancer mutations on the Combinati Absolute Q platform.